Heron Therapeutics to Present at the JMP Securities Life Sciences Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company focused on improving the lives of patients by developing
best-in-class medicines that address major unmet medical needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of
Heron Therapeutics, will present at the JMP Securities Life Sciences Conference Wednesday, June 22, 2016, at 2:30 p.m. ET (11:30
a.m. PT) in New York, New York.
A live webcast of this presentation and accompanying slides will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the
site for 60 days.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives of patients by developing best-in-class
medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative
science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron’s goal is to
build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their
potential field of use. For more information, visit www.herontx.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of
this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These
risks and uncertainties include, but are not limited to, those associated with: the projected sufficiency of our capital position
for future periods, the review of the SUSTOL NDA by the FDA, the potential market opportunity for SUSTOL and new products
generally, expected timing and acceptance of the SUSTOL commercial launch, the progress in the research and development of HTX-019,
HTX-011 and our other programs, including the timing of preclinical, clinical, and manufacturing activities, safety and efficacy
results from our studies, and other risks and uncertainties identified in the Company's filings with the Securities and Exchange
Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or
revise these statements except as may be required by law.
Investor Relations and Media Contact:
Heron Therapeutics, Inc.
Jennifer Capuzelo, 858-703-6063
Associate Director, Investor Relations
jcapuzelo@herontx.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160615005330/en/